KR101529743B1 - 재조합적으로 변형된 플라스민 - Google Patents

재조합적으로 변형된 플라스민 Download PDF

Info

Publication number
KR101529743B1
KR101529743B1 KR1020107014243A KR20107014243A KR101529743B1 KR 101529743 B1 KR101529743 B1 KR 101529743B1 KR 1020107014243 A KR1020107014243 A KR 1020107014243A KR 20107014243 A KR20107014243 A KR 20107014243A KR 101529743 B1 KR101529743 B1 KR 101529743B1
Authority
KR
South Korea
Prior art keywords
pro
gly
thr
ser
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107014243A
Other languages
English (en)
Korean (ko)
Other versions
KR20100102135A (ko
Inventor
밸러리 노보카트니
Original Assignee
그리폴스 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그리폴스 테라퓨틱스 인코포레이티드 filed Critical 그리폴스 테라퓨틱스 인코포레이티드
Publication of KR20100102135A publication Critical patent/KR20100102135A/ko
Application granted granted Critical
Publication of KR101529743B1 publication Critical patent/KR101529743B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020107014243A 2007-11-29 2008-11-25 재조합적으로 변형된 플라스민 Expired - Fee Related KR101529743B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99114807P 2007-11-29 2007-11-29
US60/991,148 2007-11-29
PCT/US2008/084645 WO2009073471A1 (en) 2007-11-29 2008-11-25 Recombinantly modified plasmin

Publications (2)

Publication Number Publication Date
KR20100102135A KR20100102135A (ko) 2010-09-20
KR101529743B1 true KR101529743B1 (ko) 2015-06-17

Family

ID=40379999

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107014243A Expired - Fee Related KR101529743B1 (ko) 2007-11-29 2008-11-25 재조합적으로 변형된 플라스민

Country Status (17)

Country Link
US (3) US8101394B2 (https=)
EP (1) EP2220221B1 (https=)
JP (1) JP5539896B2 (https=)
KR (1) KR101529743B1 (https=)
CN (1) CN101918548B (https=)
AU (1) AU2008331545B2 (https=)
BR (1) BRPI0819780B1 (https=)
CA (1) CA2707266C (https=)
ES (1) ES2534040T3 (https=)
HU (1) HUE024916T2 (https=)
IL (1) IL205936A (https=)
MX (1) MX2010005947A (https=)
NZ (2) NZ593837A (https=)
PL (1) PL2220221T3 (https=)
PT (1) PT2220221E (https=)
WO (1) WO2009073471A1 (https=)
ZA (1) ZA201003730B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102660564B (zh) 2004-04-22 2013-05-08 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
PL2220221T3 (pl) 2007-11-29 2015-07-31 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
MX2010013282A (es) 2008-06-04 2010-12-21 Talecris Biotherapeutics Inc Composicion, metodo y kit para la preparacion de plasmina.
HUE025670T2 (en) * 2009-03-03 2016-04-28 Grifols Therapeutics Inc A method for producing plasminogen
WO2011004011A1 (en) 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
CN102121023B (zh) * 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
JP6085568B2 (ja) 2011-01-05 2017-02-22 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants
CN103205410B (zh) * 2012-01-13 2018-03-06 蔺莹莹 重组微纤维蛋白溶酶及其制备方法和应用
SG11201506886TA (en) 2013-03-14 2015-09-29 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
DE102014112212A1 (de) * 2014-08-26 2016-03-03 Akesion Gmbh Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen
FR3035120B1 (fr) * 2015-04-15 2020-02-07 Arcadophta Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition
WO2017101870A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法
TWI725092B (zh) 2015-12-18 2021-04-21 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途
TWI624268B (zh) 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑
WO2017101867A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
CN108210897A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肺纤维化的药物及其用途
WO2018107707A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
JP7175270B2 (ja) * 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
WO2018107688A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂肪肝的方法
US11154595B2 (en) 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
US11140020B1 (en) 2018-03-01 2021-10-05 Amazon Technologies, Inc. Availability-enhancing gateways for network traffic in virtualized computing environments
WO2020152713A1 (en) * 2019-01-25 2020-07-30 Council Of Scientific & Industrial Research Fibrinolytic composition and method of its preparation
CN115697385A (zh) * 2020-05-11 2023-02-03 泰伦基国际有限公司 一种治疗脊髓性肌萎缩症的方法和药物
CN118308334B (zh) * 2024-06-06 2024-10-08 深圳市卫光生物制品股份有限公司 一种重组人纤溶酶原及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105990A2 (en) * 2004-04-22 2005-11-10 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
WO2007047874A2 (en) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
DE69739304D1 (de) 1996-01-23 2009-04-23 Operon Biotechnologies Inc Verfahren und Zusammensetzungen zur Bestimmung von Sequenzen von Nukleinsäure-Molekülen
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
JPH10158300A (ja) 1996-11-28 1998-06-16 Suzuki Motor Corp 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法
JP2001511362A (ja) 1997-07-22 2001-08-14 ラピジーン，インコーポレイテッド Ｍｓにより配列決定データを相関させるコンピュータ方法およびシステム
AU751283B2 (en) 1998-07-14 2002-08-08 Bristol-Myers Squibb Company Lysine binding fragments of angiostatin
ATE349226T1 (de) 1998-09-29 2007-01-15 Leuven Res & Dev Vzw Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
AU2001275091A1 (en) 2000-06-02 2001-12-17 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
JP4047170B2 (ja) 2000-12-21 2008-02-13 トロム−イクス・ナムローゼ・フエンノートシャップ 酵母発現ベクターおよび酵母細胞における発現による組換えタンパク質の製造方法
WO2003054232A2 (en) 2001-12-13 2003-07-03 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
DE10390418D2 (de) 2002-02-06 2005-01-13 N Zyme Biotec Gmbh Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
GB0228409D0 (en) * 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
PL2220221T3 (pl) 2007-11-29 2015-07-31 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105990A2 (en) * 2004-04-22 2005-11-10 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
WO2005105990A3 (en) 2004-04-22 2006-01-12 Talecris Biotherapeutics Inc Recombinantly modified plasmin
WO2007047874A2 (en) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin

Also Published As

Publication number Publication date
KR20100102135A (ko) 2010-09-20
HK1146089A1 (en) 2011-05-13
IL205936A0 (en) 2010-11-30
US8512980B2 (en) 2013-08-20
BRPI0819780B1 (pt) 2023-01-24
ES2534040T3 (es) 2015-04-16
MX2010005947A (es) 2010-09-10
CN101918548A (zh) 2010-12-15
NZ585715A (en) 2011-11-25
IL205936A (en) 2015-04-30
CN101918548B (zh) 2013-10-16
EP2220221A1 (en) 2010-08-25
US20120276611A1 (en) 2012-11-01
CA2707266C (en) 2013-12-31
US8182808B2 (en) 2012-05-22
BRPI0819780A2 (pt) 2015-08-11
JP2011505140A (ja) 2011-02-24
EP2220221B1 (en) 2014-12-31
AU2008331545B2 (en) 2014-01-16
HUE024916T2 (en) 2016-02-29
WO2009073471A1 (en) 2009-06-11
AU2008331545A1 (en) 2009-06-11
US8101394B2 (en) 2012-01-24
US20120093799A1 (en) 2012-04-19
CA2707266A1 (en) 2009-06-11
US20110003332A1 (en) 2011-01-06
PT2220221E (pt) 2015-04-16
ZA201003730B (en) 2012-11-28
JP5539896B2 (ja) 2014-07-02
PL2220221T3 (pl) 2015-07-31
NZ593837A (en) 2013-01-25

Similar Documents

Publication Publication Date Title
KR101529743B1 (ko) 재조합적으로 변형된 플라스민
US8420079B2 (en) Recombinantly modified plasmin
HK1175812B (en) Recombinantly modified plasmin
HK1099341B (en) Recombinantly modified plasmin
HK1150242B (en) Recombinantly modified plasmin
HK1146089B (en) Recombinantly modified plasmin

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180319

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190312

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20200224

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240612

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240612